详情页 - 广东省中医院知识库

当前位置：首页 > 详情页

Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2

12| 认领 | 链接全文 |

文献详情

编号/登记号：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究类型：

研究参与人：

研究单位： [1]Affiliated Tumor Hospital of Guangzhou Medical University Recruiting [2]Tianjin Medical University Cancer Institute and Hospital [3]Nanfang Hospital of Southern Medical University [4]Zhejiang Cancer Hospital [5]The Second Hospital of Hebei Medical University [6]Chinese PLA General Hospital [7]Henan Cancer Hospital [8]Harbin Medical University [9]Central South University [10]Guangdong Provincial People's Hospital [11]Wuhan Union Hospital, China [12]Sun Yat-sen University [13]Hebei Medical University Fourth Hospital [14]Guangdong Provincial Hospital of Traditional Chinese Medicine

关键词： locally advanced gastric cancer Hyperthermic Intraperitoneal Chemotherapy radical gastrectomy with D2 lymphadenectomy

研究目的：

HIPEC-01 is a prospective, open, randomized multicenter phase III clinical study conducted in China. To determine the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of locally advanced gastric cancer, patients are randomized into HIPEC group and control group. In HIPEC group, the patients undergo radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and postoperative chemotherapy. Patients in the control group just undergo radical gastrectomy with D2 lymphadenectomy followed by postoperative chemotherapy. Patients in both groups receive 6-8 cycles of postoperative systemic chemotherapy (XELOX or SOX regimens) and are followed up for 5 years or until death.